Precision BioSciences
Yahoo Finance • 11 months ago
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Precision BioSciences, Inc. (NASDAQ: DTIL) and Encourages Investors to Contact the Firm
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Precision BioSciences, Inc. (NASDAQ: DTIL) (“Precision”) on behalf of the company’s investors. Since November 2022, shares of Precision’s... Full story
Yahoo Finance • 11 months ago
Precision BioSciences Inc (DTIL) Reports Q3 2023 Financial Results
Revenues for Q3 2023 were $13.1 million, a significant increase from $7.4 million in Q3 2022. Net loss for the quarter was $8.1 million, or $(0.07) per share, including $4.0 million income from discontinued operations. The company complete... Full story
Yahoo Finance • 11 months ago
Precision BioSciences to Report Third Quarter Results on November 7, 2023
DURHAM, N.C., November 01, 2023--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene... Full story
Yahoo Finance • 2 years ago
Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting
- Cryopreserved, Post-thaw CAR T Cell Composition and Effective CAR T Cell Dose are Predictive for Response to Treatment with Azer-cel - Peak CAR T Expansion, a Key Determinant of Durable Response, Strongly Correlated with Effective CAR T... Full story
Yahoo Finance • 2 years ago
Precision BioSciences Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., October 26, 2022--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an indu... Full story
Yahoo Finance • 2 years ago
Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug
Editas Medicine, Inc. EDIT is making good progress with the development of its lead pipeline candidate, EDIT-101, which employs CRISPR gene editing, to treat Leber congenital amaurosis type 10 (LCA10) — a rare genetic illness that causes b... Full story
Yahoo Finance • 2 years ago
Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why
Shares of Acadia Pharmaceuticals Inc. ACAD have plunged 33.5% in the past three months compared with the industry’s decrease of 7.6%. Zacks Investment Research Image Source: Zacks Investment Research The company’s sole marketed drug, Nup... Full story
Yahoo Finance • 2 years ago
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population
PBCAR0191 Achieved 100% Response Rate (ORR), 73% Complete Response (CR) Rate and 50% Durable Response Greater than Six Months Among Evaluable CAR T Relapsed Subjects PBCAR0191 Achieved Peak CAR T Cell Expansion Matching Data from Autologo... Full story
Yahoo Finance • 2 years ago
Precision BioSciences to Provide an Update on its Ongoing Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on Wednesday, June 8, 2022
DURHAM, N.C., June 03, 2022--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Co... Full story
Yahoo Finance • 2 years ago
Precision BioSciences to Participate in Upcoming Jefferies Healthcare Conference
DURHAM, N.C., June 03, 2022--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Co... Full story
Yahoo Finance • 2 years ago
Triangle market caps keep tanking – Duke economist explains the volatility
The public markets plunge continues, with a Raleigh technology firm’s market cap tanking 82 percent year-over-year – just one of many firms feeling the pressure. A review of market cap data conducted by the Business Journals shows virtuall... Full story
Yahoo Finance • 2 years ago
Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update
- PBCAR0191, PBCAR19B and PBCAR269A Allogeneic CAR T Program Updates Planned for June 2022 - Three Wholly Owned In Vivo Gene Editing Programs Progressing Toward IND or CTA in the Next Three Years - Preclinical In Vivo Gene Editing Data f... Full story
